Research Study for Children with Growth Hormone Excess
Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.
Study Design:
- All visits include medical history, physical exam, and questionnaires
- Participants will have regular blood tests and imaging studies
- All study-related evaluations and medications are free
- Travel and lodging assistance will be provided
Who can participate?
- People 2 -18 years old* with GH excess for whom surgical treatment has not worked or who are not eligible for that
- Insulin-like growth factor-1 (IGF-1) greater than the upper limit of normal for age and gender
- Elevated growth hormone levels
- Not currently taking other medications for the management of growth hormone excess
* Parents must give permission for minors to participate.
The NIH Clinical Center, America's Research Hospital, is located on the Metro Red Line (Medical Center stop) in Bethesda, MD.
For more information:
Office of Patient Recruitment
800-411-1222
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov
Or go online:
https://go.usa.gov/xyqQu
(Refer to study # 19-CH-0071)
Department of Health and Human Services
National Institutes of Health Clinical Center
National Institute of Child Health and Human Development